Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

51.44
-2.7700-5.11%
Pre-market: 51.840.4000+0.78%08:32 EDT
Volume:5.97M
Turnover:312.34M
Market Cap:8.55B
PE:-14.78
High:55.50
Open:54.88
Low:51.31
Close:54.21
52wk High:86.74
52wk Low:50.01
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.48
T/O Rate:3.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:19.44
PE(LYR):-21.60

Loading ...

Ionis Pharmaceuticals (IONS) Could Be 19% Undervalued After REVEAL Study Enrollment Milestone

Simply Wall St.
·
Jul 07

Ionis Completes Enrollment in Pivotal Phase 3 Reveal Cohort for Angelman Drug Obudanersen

Reuters
·
Jul 06

Ionis Pharmaceuticals - to Initiate Phase 3 Champion Study of Obudanersen Before End of 2026

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Topline Data from Reveal Study Expected in Second Half of 2027

THOMSON REUTERS
·
Jul 06

Ionis Pharmaceuticals - Adult Cohort Expected to Complete Enrollment in Q3 2026

THOMSON REUTERS
·
Jul 06

Ionis Completes Enrollment in Pivotal Cohort of the Phase 3 Reveal Study Evaluating Obudanersen in Angelman Syndrome

THOMSON REUTERS
·
Jul 06

Ionis EVP, Chief Clinical Development Officer Eugene Schneider Disposes of 26,000 Shares for $2.11 Million

Reuters
·
Jul 01

Ionis EVP Research Eric Swayze Sells 10,602 Shares for $839,082.60

Reuters
·
Jun 27

Movement Alert|Ionis Pharmaceuticals Rises 5.32% in Regular Trading, Zilganersen Global Commercialization Accelerates via Recordati Licensing Deal

Market Focus
·
Jun 26

Ionis Pharmaceuticals Inc : Piper Sandler Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Wells Fargo Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jun 25

Ionis Licenses Alexander Disease Drug Zilganersen to Recordati Outside US for $30 Million Upfront

Reuters
·
Jun 25

Ionis Pharmaceuticals - Plans Independent U.S. Launch of Zilganersen; FDA Pdufa Date Set for September 22

THOMSON REUTERS
·
Jun 25

Ionis Announces License Agreement with Recordati for Zilganersen in Alexander Disease (axd) in All Countries Outside the U.S.

THOMSON REUTERS
·
Jun 25

Ionis Pharmaceuticals - to Retain U.S. Commercial Rights and Lead Global Development of Zilganersen

THOMSON REUTERS
·
Jun 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), uniQure (QURE)

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals price target raised to $75 from $74 at Goldman Sachs

TIPRANKS
·
Jun 25

Ionis Pharmaceuticals - Tryngolza Available in 50 Mg or 80 Mg Dose, Self-administered Monthly

THOMSON REUTERS
·
Jun 25

Tryngolza® (olezarsen) Approved by the FDA as the First and Only Treatment to Reduce Triglycerides and the Risk of Acute Pancreatitis in Patients with Severe Hypertriglyceridemia (shtg)

THOMSON REUTERS
·
Jun 25